Arctic Bioscience AS (OSL:ABS)

Market Cap	150.95M
Revenue (ttm)	31.88M
Net Income (ttm)	-48.37M
Shares Out	25.37M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,361
Average Volume	89,325
Open	5.75
Previous Close	5.75
Day's Range	5.75 - 6.30
52-Week Range	1.65 - 16.80
Beta	1.61
RSI	70.87
Earnings Date	May 7, 2025

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand worldwide. The company was incorporated in 2011 and is headquartered in Ørsta, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 355
• Stock Exchange: Oslo Børs
• Ticker Symbol: ABS

Financial Performance

In 2023, Arctic Bioscience AS's revenue was 33.76 million, a decrease of -2.07% compared to the previous year's 34.47 million. Losses were -45.51 million, 33.8% more than in 2022.